TRC105联合帕唑帕尼对比帕唑帕尼单药治疗晚期血管肉瘤的适应性人群富集III期试验(TAPPAS)设计
TAPPAS是一项在晚期血管肉瘤患者中比较TRC105(carotuximab)联合帕唑帕尼与帕唑帕尼单药的III期试验。鉴于该病为超罕见肿瘤且缺乏可靠历史数据,研究采用适应性设计,包含人群富集和样本量重估计,并获FDA特殊方案评估。该设计较传统单次分析设计能通过期中非盲数据分析提升把握度。
要点
- TAPPAS试验采用适应性设计,针对超罕见血管肉瘤开展人群富集和样本量重估计。
- 设计获得FDA特殊方案评估及EMA监管输入,注册号NCT02979899。
- 适应性设计较传统单次分析设计可通过期中非盲分析学习并提升统计把握度。
核心结论
- 在超罕见肿瘤中采用适应性设计可克服患者有限和历史数据缺乏的挑战,并通过期中分析提升统计把握度。
研究设计与样本
- TAPPAS是一项III期试验,比较TRC105联合帕唑帕尼与帕唑帕尼单药在晚期血管肉瘤患者中的疗效。
- 设计包含适应性人群富集和样本量重估计,并获FDA特殊方案评估及EMA监管输入。
主要发现
- I/II期研究显示TRC105联合帕唑帕尼安全,并出现持久完全缓解和鼓舞人心的无进展生存期。
- I/II期研究提示皮肤病变患者较非皮肤病变患者可能有更优获益。
临床怎么用
- 该试验设计为超罕见肿瘤的临床研究提供了适应性方法学参考,尚待试验结果公布后指导临床实践。
局限性
- 血管肉瘤为超罕见病,患者数量有限且缺乏可靠历史数据用于估计疗效和样本量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Major challenges in clinical trials of ultra-orphan oncology diseases include limited patient availability and paucity of reliable prior data for estimating the treatment effect and, therefore, determining optimal sample size. Angiosarcoma (AS), a particularly aggressive form of soft tissue sarcoma with an incidence of about 2000 cases per year in the United States and Europe is poorly addressed by current systemic therapies. Pazopanib, an inhibitor of vascular endothelial growth factor receptor (VEGFR) is approved for the treatment of AS, with modest benefit. TRC105 (carotuximab) is a monoclonal antibody to endoglin, an essential angiogenic target highly expressed on proliferating endothelium and both tumor vessels and tumor cells in AS, that has the potential to complement VEGFR tyrosine kinase inhibitors. In a phase I/II study of soft tissue sarcoma, TRC105 combined safely with pazopanib and the combination demonstrated durable complete responses and encouraging progression-free survival (PFS). In addition, there was a suggestion of superior benefit in patients with cutaneous lesions versus those with the non-cutaneous lesions. PATIENTS AND METHODS: This article describes the design of a recently initiated phase III trial of TRC105 And Pazopanib versus Pazopanib alone in patients with advanced AngioSarcoma (TAPPAS trial). Given the ultra-orphan status of the disease and the paucity of reliable prior data on PFS or overall survival (end points required for regulatory approval as a pivotal trial), an adaptive design incorporating population enrichment and sample size re-estimation was implemented. The design incorporated regulatory input from the Food and Drug Administration (FDA) and European Medicines Agency and proceeded following special protocol assessment designation by the FDA. CONCLUSIONS: It is shown that the benefit of the adaptive design as compared with a conventional single-look design arises from the learning and subsequent improvements in power that occur after an unblinded analysis of interim data. REGISTERED ON CLINICALTRIALS.GOV: NCT02979899.
引用
- Mehta CR, Liu L, Theuer C, et al. An adaptive population enrichment phase III trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma (TAPPAS trial). Ann Oncol. 2019. PMID: 30357394. doi:10.1093/annonc/mdy464
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。